NEWS
News Articles
Pfizer-BioNTech Booster Shot Restores Full Covid Protection
Trial was run in period when delta was dominant Covid strain Results may strengthen case for giving third doses more widely Pfizer Inc. and BioNTech SE said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely. A booster was…
Read MoreGeoVax Receives Notice of Allowance for Ebola Vaccine Patent
Single-dose of GEO-EM01 Provided 100% Protection in Lethal Challenge Evaluation ATLANTA, GA, October 14, 2021 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for Patent Application No. 15/543,139 entitled “Replication-Deficient…
Read MoreFrancis Collins to step down as director of the National Institutes of Health
Francis S. Collins, M.D., Ph.D., today announced his decision to end his tenure as the director of the National Institutes of Health by the end of the year. Dr. Collins is the longest serving presidentially appointed NIH director, having served three U.S. presidents over more than 12 years. “It has been an incredible privilege to…
Read MoreEmory University research helps develop potential COVID-19 treatment drug
Emory University researchers have helped develop an oral antiviral drug that could treat COVID-19, a potential breakthrough in the ongoing pandemic. Merck and Ridgeback Biotherapeutics announced Friday they plan to seek emergency use authorization from federal health officials for the drug, molnupiravir, after research showed “compelling” results in clinical trials. If approved, it would be…
Read MorePfizer and Voyager Launch $630 Million Gene Therapy Technology Pact
Cambridge, Mass.-based Voyager Therapeutics entered a deal with Pfizer, allowing the latter to exercise options to license novel capsids for gene therapies. Specifically, the deal enables Pfizer to license novel capsids created by Voyager’s RNA-driven TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) screening technology. Pfizer will pay $30 million upfront and $20 million in exercise fees for a pair…
Read MoreMeet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D
Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a biotech that starts life with $500 million, a collaboration with Amgen and a pipeline of eight prospects. Neumora represents a test of the idea that neuroscience is…
Read More